ストックスクリーナーアプリを入手
65.67
2.78%
-1.88
前日終値:
$67.55
開ける：
$67.72
24時間の取引高:
1.43M
Relative Volume:
0.26
時価総額：
$10.34B
収益：
当期純損益:
$-946.53M
株価収益率:
-9.4267
EPS:
-6.9664
ネットキャッシュフロー:
$-814.94M
1週間 パフォーマンス:
+1.01%
1か月 パフォーマンス:
+10.91%
6か月 パフォーマンス:
+8.64%
1年 パフォーマンス:
+49.45%
1日の値動き範囲:
$65.00
$68.33
1週間の範囲:
$64.78
$72.89
52週間の値動き範囲:
$39.87
$90.75
Vaxcyte Inc Stock (PCVX) Company Profile
名前
Vaxcyte Inc
セクター
電話
650-837-0111
住所
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
65.67 | 10.34B | 0 | -946.53M | -814.94M | -6.9664 |
VRTX
Vertex Pharmaceuticals Inc
|
508.15 | 128.80B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.82 | 95.35B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.63 | 82.33B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.39 | 53.54B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
373.90 | 42.30B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 繰り返されました | Needham | Buy |
| 2025-09-12 | 開始されました | Goldman | Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-20 | 開始されました | Goldman | Buy |
| 2023-12-07 | 開始されました | Mizuho | Buy |
| 2023-04-18 | 開始されました | TD Cowen | Outperform |
| 2023-01-03 | 繰り返されました | Needham | Buy |
| 2022-12-15 | 開始されました | Guggenheim | Buy |
| 2022-11-17 | 開始されました | BTIG Research | Buy |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-06-24 | 再開されました | Jefferies | Buy |
| 2020-07-07 | 開始されました | BofA Securities | Buy |
| 2020-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 開始されました | Needham | Buy |
すべてを表示
Vaxcyte Inc (PCVX) 最新ニュース
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet - Zacks Investment Research
Vaxcyte EVP, COO Jim Wassil sells $1.56m in shares By Investing.com - Investing.com South Africa
Vaxcyte EVP, COO Jim Wassil sells $1.56m in shares - Investing.com
Vaxcyte Finalizes $575M Convertible Senior Notes and Equity Offering in October 2026 - Kalkine Media
Vaxcyte Closes Offerings of Common Stock, Warrants, and Senior Notes - marketscreener.com
Vaxcyte Announces Closing of $1.15 Billion Public Offerings - GlobeNewswire
Vaxcyte Inc Stock (PCVX) Moved Up by 9.47% on Oct 9: What Signal Does It Send? - TradingKey
Latham Advises on Vaxcyte Concurrent Public Offerings of Common Stock Pre Funded Warrants - Latham & Watkins LLP
Vaxcyte Announces Pricing for $500M Convertible Notes and 7.4M Share Offering - Kalkine Media
About $500 million is expected from stock and $500 million from bonds. Vaxcyte plans to fund vaccine work. - Stock Titan
Vaxcyte prices US$1B in stock, warrants and convertible notes - Mugglehead Investment Magazine
Vaxcyte stock reports OPUS-1 success after a 9.65 percent drop - AD HOC NEWS
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes - GlobeNewswire Inc.
Vaxcyte Announces Pricing of Concurrent Public Offerings of - GlobeNewswire
Biotech Stocks At 52-Week HighsPCVX +31% On Phase 3 Results, INFU, ILMN +7%, CRL+7%, HTFL +5% - RTTNews
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? - Zacks Investment Research
Two proposed $500 million offerings could fund Vaxcyte vaccine trials and U.S. launch preparations. - stocktitan.net
Vaxcyte stock falls on $1B dual offering launch - Yahoo Finance
Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge - The Motley Fool
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes - marketscreener.com
Vaxcyte, Inc.Common Stock (Nasdaq:PCVX) Stock Quote - FinancialContent
An officer proposes to sell $1.65M in Vaxcyte (PCVX) shares acquired by exercising stock options. - Stock Titan
An officer proposes selling Vaxcyte (PCVX) shares acquired by exercising stock options for cash. - stocktitan.net
Vaxcyte, Inc. (PCVX) Stock Price, News, Quote & History - ca.finance.yahoo.com
Vaxcyte EVP Jim Wassil Executes Stock Option and Sells Shares via Rule 10b5-1 Plan - Kalkine Media
A 2,250-share sale is proposed by Vaxcyte (PCVX) officer James Wassil. - Stock Titan
Total common shares outstanding of Vaxcyte, Inc. – HAN:5VA - TradingView
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research
Trading the Move, Not the Narrative: (PCVX) Edition - Stock Traders Daily
Vaxcyte EVP Jim Wassil sells $163,862 in company stock By Investing.com - Investing.com South Africa
Vaxcyte CFO Andrew Guggenhime Forfeits 7,155 Shares, 7% of Holdings at $60.36 Each - Kalkine Media
Vaxcyte EVP Jim Wassil sells $163,862 in company stock By Investing.com - Investing.com Nigeria
Vaxcyte EVP Jim Wassil sells $163,862 in company stock By Investing.com - Investing.com Canada
Vaxcyte EVP Jim Wassil sells $163,862 in company stock - Investing.com
Vaxcyte (PCVX) officer plans stock sale after RSU vest - Stock Titan
Vaxcyte at Cantor conference: broad vaccine bet nears key test By Investing.com - Investing.com Canada
PCVX: VAX-31 phase III data expected by end of October, targeting broader pneumococcal protection - TradingView
Vaxcyte EVP Jim Wassil sells $163,862 in company stock - Investing.com
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes By Investing.com - Investing.com Nigeria
Why Are Vaxcyte (NASDAQ:PCVX) Shares Under Pressure After A Timeline Update? - Kalkine Media
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes By Investing.com - Investing.com Canada
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes By Investing.com - Investing.com UK
Vaxcyte Executive Sells Shares for Tax Obligations - Intellectia AI
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - The Globe and Mail
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know - The Globe and Mail
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - The Globe and Mail
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - The Motley Fool
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm - The Motley Fool
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - Yahoo Finance
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know - The Globe and Mail
Vaxcyte Inc (PCVX) 財務データ
収益
当期純利益
現金流量
EPS
Vaxcyte Inc (PCVX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Cowan Elvia | Officer |
Oct 05 '26 |
Proposed Sale |
86.74 |
19,000 |
1,648,060 |
0 |
| Wassil Jim | Officer |
Oct 05 '26 |
Proposed Sale |
86.74 |
18,000 |
1,561,320 |
0 |
| Wassil Jim | EVP, Chief Scientific Ofc, COO |
Oct 05 '26 |
Sale |
86.74 |
18,000 |
1,561,320 |
145,435 |
| Cowan Elvia | SVP, Finance & CAO |
Oct 05 '26 |
Option Exercise |
25.92 |
19,000 |
492,480 |
46,860 |
| Cowan Elvia | SVP, Finance & CAO |
Oct 05 '26 |
Sale |
86.74 |
19,000 |
1,648,060 |
27,860 |
| Wassil Jim | EVP, Chief Scientific Ofc, COO |
Oct 01 '26 |
Sale |
56.67 |
2,250 |
127,513 |
145,435 |
| Wassil Jim | EVP, Chief Scientific Ofc, COO |
Oct 01 '26 |
Option Exercise |
5.35 |
2,250 |
12,038 |
147,685 |
| Wassil Jim | Officer |
Oct 01 '26 |
Proposed Sale |
56.73 |
2,250 |
127,642 |
0 |
| Wassil Jim | Officer |
Sep 09 '26 |
Proposed Sale |
59.99 |
1,334 |
80,027 |
0 |
| Wassil Jim | EVP, Chief Scientific Ofc, COO |
Sep 09 '26 |
Sale |
59.52 |
1,334 |
79,401 |
145,435 |
0.66%
0.02%
大文字化:
|
ボリューム (24 時間):